Common Topical Application Patterns Use case Facial anti-aging (community use) Concentration 1-2% Frequency Once or twice daily Cycle length 8-12 weeks Use case Scalp / hair-research interest Concentration 1-3% Frequency Daily Cycle length 12+ weeks ongoing Use case Compounded post-procedure Concentration 1-2% Frequency Per clinician guidance Cycle length Per clinician guidance Topical concentrations are typically expressed as percent weight
The promise is real, but clinical readiness is not: Preclinical and early human data are compelling, but without large-scale trials, validated delivery methods, and long-term safety data, Epitalon remains an experimental peptide, one to watch closely, but not yet ready for mainstream clinical adoption
Hemolysis ratio (%) = (A A n )/(A p A n ) 100%, where A represents the absorbance value for the sample group, A p represents the absorbance value for the positive group and A n is the absorbance value for the negative group
A universal claim that everyone loses exactly 50% of NAD+ by age 50 is not supported by a single standard clinical measurement